help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-2614
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanley, A. J. G.
Right arrow Articles by Haffner, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanley, A. J. G.
Right arrow Articles by Haffner, S. M.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 7 2665-2671
Copyright © 2007 by The Endocrine Society

Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans

Anthony J. G. Hanley, Donald Bowden, Lynne E. Wagenknecht, Aarthi Balasubramanyam, Carl Langfeld, Mohammed F. Saad, Jerome I. Rotter, Xiuqing Guo, Yii-Der I. Chen, Michael Bryer-Ash, Jill M. Norris and Steven M. Haffner

Departments of Nutritional Sciences and Medicine (A.J.G.H.), University of Toronto, Toronto, Ontario, Canada M5S 3E2; Division of Clinical Epidemiology (A.J.G.H., S.M.H.), University of Texas Health Science Center, San Antonio, Texas 78229-3900; Department of Biochemistry (D.B.) and Division of Public Health Sciences (L.E.W., A.B., C.L.), Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157; State University of New York at Stony Brook (M.F.S.), Stony Brook, New York, New York 11794; Medical Genetics Institute (J.I.R., X.G., Y.-D.I.C.), Cedars-Sinai Medical Center, Los Angeles, California 90048; David Geffen School of Medicine at University of California Los Angeles (M.B.-A.), Los Angeles, California 90095; and Department of Preventive Medicine and Biometrics (J.M.N.), University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262

Address all correspondence and requests for reprints to: Steven Haffner, M.D., M.P.H., Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center, Mail Code 7873, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: haffner{at}uthscsa.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: Hypoadiponectinemia has emerged as an independent risk factor for type 2 diabetes and cardiovascular disease. Although associations of adiponectin with central obesity and insulin resistance have been reported, very little data are available from studies using detailed measures of insulin sensitivity (SI) and/or body fat distribution in ethnic groups at high risk for metabolic disease.

Objective: The aim of the study was to identify the correlates of adiponectin in 1636 nondiabetic Hispanics and African-Americans.

Design: A cross-sectional analysis of participants in the Insulin Resistance Atherosclerosis Family Study was conducted. SI was determined from frequently sampled iv glucose tolerance tests with minimal model analysis. Subcutaneous and visceral adipose tissues (SAT, VAT, respectively) were determined with computed tomography. Triglyceride, high-density lipoprotein, C-reactive protein, and adiponectin were measured in fasting samples. Generalized estimating equation (GEE) models were used to identify factors associated with adiponectin concentration.

Setting: A multicenter study using a family-based design was conducted.

Participants: A total of 1636 nondiabetic Hispanic and African-American subjects participated.

Main Outcome Measures: Circulating adiponectin concentration was measured.

Results: Age, female gender, high-density lipoprotein, SAT, and SI were positive independent correlates of adiponectin, whereas glucose, CRP, and VAT were negative independent correlates (all P < 0.05). Ethnicity was not an independent correlate of adiponectin in this model (P = 0.27); however, an ethnicity by VAT interaction term was retained, indicating a stronger negative association of VAT with adiponectin in African-Americans compared with Hispanics.

Conclusion: Directly measured SI, VAT, and SAT were independently correlated with adiponectin in Hispanic and African-American subjects. The inverse association of VAT with adiponectin was stronger in African-Americans compared with Hispanics, a finding that suggests possible ethnic differences in the effects of visceral obesity.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
ADIPONECTIN, A 30-Kd collagen-like protein produced and secreted exclusively from adipose tissue, is emerging as a predominant adipokine in the pathobiology of the metabolic syndrome (1, 2, 3, 4). Included in its growing list of pleiotropic properties are insulin-sensitizing, antidiabetic, antiatherogenic, antiinflammatory, and antioxidant effects (1, 2, 3, 4, 5). In cross-sectional studies, subjects with type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease (CVD) have consistently had reduced adiponectin concentrations (6, 7, 8). Prospective studies have reported that hypoadiponectinemia is a consistent and independent predictor of incident type 2 diabetes (9, 10, 11) and, in the majority of studies to date, CVD events (12, 13, 14, 15).

Adiponectin circulates in high concentrations in the plasma. A number of factors have been studied for their role in determining circulating adiponectin concentrations, including genetic polymorphisms and chromosomal loci (16, 17), gender (18, 19), pharmacological agents (20, 21), sex hormones (22), insulin sensitivity (SI) (18, 23, 24), adiposity (1, 2, 3, 4, 5, 6, 7, 8, 18, 25, 26, 27), and ethnicity (11, 23, 28, 29, 30, 31, 32, 33, 34, 35). Although inverse associations with indirect measures of anthropometry and SI, including as body mass index (BMI), waist circumference, and insulin concentrations, have been consistently demonstrated (1, 2, 3, 4, 5, 6, 7, 8), fewer data on direct measures of adipose tissue depots and SI are available (18, 25, 26, 27). In addition, while a limited number of studies have reported lower adiponectin levels in African-Americans, Pima Indians, and South Asians compared with whites (11, 23, 28, 29, 30, 31, 32, 33, 34, 35), little information has been presented to explain the biological mechanisms underlying these ethnic differences. Furthermore, levels of adiponectin in Hispanics relative to other groups have received limited study (35). Understanding the determinants of nontraditional metabolic risk factors such as adiponectin in different ethnic groups is of value, given marked differences in the burden of chronic disease across these populations in Westernized countries (36, 37).

The objective of the present study was to identify the correlates of adiponectin concentration in a large group of Hispanic and African-American participants in the Insulin Resistance Atherosclerosis (IRAS) Family Study. Subjects in this study have been extremely well characterized, including directly measured visceral and sc adipose tissue (VAT and SAT, respectively) and SI, in addition to a wide range of other traditional and nontraditional risk factors for diabetes and CVD. We hypothesize that previously reported lower concentrations of adiponectin among African-Americans may be explained by unique metabolic and anthropometric characteristics of this population.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
The methodology of the IRAS Family Study has been described in detail in previous publications (38, 39). Briefly, the study was designed to explore genetic contributions to insulin resistance and visceral adiposity among Hispanics and African-Americans using a family-based design (38). Large families were recruited between 2000 and 2002 at centers in San Antonio, TX, San Luis Valley, CO (Hispanics), and Los Angeles, CA (African-Americans), with probands identified from the parent study [IRAS (38)] as well as the general population. The present cross-sectional analysis included 1636 subjects who were free of diabetes (self-report or fasting glucose ≥ 126 mg/dl), and for whom information was available on adiponectin, SI, SAT, VAT, and other variables of interest. The institutional review boards at the respective institutions approved the protocol, and informed consent was given by each subject.

Fat mass in the abdominal region was measured by computed tomography (CT) at both the L2/L3 and L4/L5 vertebral regions. A standardized protocol was used at each of the three clinical centers. Scans were read centrally at the University of Colorado Health Sciences Center, Department of Radiology, for SAT and VAT, with bowel fat subtracted out from measure of VAT. The L4/L5 measure was used in the present analysis. However, 45 subjects had data for the L2/L3 region, but not the L4/L5 region. Because adipose tissue areas at the L2/L3 and L4/L5 regions were highly correlated (Spearman correlation: 0.95 for SAT, 0.90 for VAT), data for these latter individuals for the L4/L5 region were imputed using a simple linear model (38, 39). SI was determined using a frequently sampled iv glucose tolerance test (40, 41, 42). SI, expressed as the SI index, was calculated using minimal model analysis (43).

Adiponectin concentration was measured using a RIA (LINCO Research, Inc., St. Charles, MO), with interassay and intraassay coefficients of variation (CVs) of 9.3%, 6.9%, and 9.3%, and 3.6%, 6.2%, and 1.8%, respectively, at concentrations of 1.5, 3.0, and 7.5 µg/ml. C-reactive protein (CRP) was measured using an in-house ultrasensitive competitive immunoassay (antibodies and antigens from Calbiochem, La Jolla, CA), with an interassay CV of 8.9% (44). Plasma glucose was measured using the glucose oxidase technique on an autoanalyzer. Impaired fasting glucose was defined as fasting glucose ≥ 100 and less than 126 mg/dl. Plasma insulin was measured using the dextran-charcoal RIA (45), which has a 19% interassay CV. Lipids were determined using standard laboratory procedures. Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. Waist circumference was measured at the natural indentation or a level midway between the iliac crest and lower edge of the rib cage if no natural indentation was present. Duplicate measures were made following a standardized protocol and averages used in the analysis. Resting blood pressure (systolic and fifth-phase diastolic) was recorded with a standard mercury sphygmomanometer after a 5-min rest. The average of the second and third measurements was used in the analysis. Ethnicity, smoking, and menopausal status were assessed by self-report.

Statistical analysis

SAS version 8.02 (SAS Institute, Inc., Cary, NC) was used for all statistical analyses. Initial univariate analyses were conducted to assess the similarity of associations of metabolic and anthropometric variables with adiponectin among Hispanic participants from the San Antonio and San Luis Valley centers. In addition, subgroup analyses, restricted to these two Hispanic groups, were conducted to determine whether there were any statistical interactions of clinical center (San Antonio vs. San Luis Valley) by VAT, SAT, or SI on adiponectin concentration.

GEEs were used to test for associations between adiponectin and the various independent variables while accounting for the familial correlations. In this application, the identity link was used. The familial correlation was modeled assuming exchangeable correlation for the working correlation matrix, and the variance was estimated via the sandwich estimator. GEEs are a standard approach to the analysis of correlated data such as family data and can be intuitively thought of as similar to linear regression models except that they account for the correlation among pedigrees. The natural logarithm of adiponectin was the response or dependent variable for all models, in which the log transformation was computed to best approximate the modeling assumptions (i.e. conditional normality, homogeneity of variance). The performance of each model was examined using standard regression diagnostics (i.e. colinearity, influence, homogeneity of variance, residuals). A multistage approach to model building was used to investigate the joint relationships of adiposity measures (VAT and SAT), SI, and ethnicity on the natural log of adiponectin. To minimize the influence of observations in the tail of the skewed distributions, VAT, SAT, and SI + 1, were also modeled on the natural log scale. The first model examined whether there were meaningful departures from linearity for each continuous variable adjusting for gender and ethnicity. Specifically, in addition to the linear effects, the corresponding quadratic effects of age, (log) VAT, (log) SAT, and (log) (SI + 1), were modeled as the squared deviation from the respective means. The nonlinear quadratic terms were statistically significant for age, (log) SAT, and (log) (SI +1), and were retained in subsequent modeling. The second model tested for the main effects of (log) VAT, (log) SAT, (log) (SI +1), and ethnicity on adiponectin. Covariates in this model included fasting glucose, gender, current cigarette smoking, systolic and diastolic blood pressure, and the natural logs of triglyceride (Tg), high-density lipoprotein (HDL), and CRP. The third set of models included tests for the following interactions: (log) VAT by (log) SAT, (log) VAT or (log) SAT by ethnicity, (log) VAT or (log) SAT by gender, and (log) (SI + 1) by ethnicity. A backward elimination procedure was used, with interactions maintained with a P value < 0.01 and main effect variables retained if any corresponding interaction was significant, or the main effect in the absence of a corresponding interaction was significant at the P value < 0.05. Results for the interaction variables indicated that only the VAT by ethnicity interaction was statistically significant under these criteria, and, therefore, this variable was retained in the final model. Separate models were also generated for the two ethnic groups using main effect variables identified during backward elimination for the full cohort. Finally, the aforementioned model was rerun using the VAT to SAT ratio in place of separate variables for VAT and SAT.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Initial analysis indicated that univariate associations of metabolic and anthropometric variables with adiponectin were similar for Hispanic participants from the two centers. In addition, in a subgroup analysis restricted to these two Hispanic groups, there were no significant statistical interactions of clinical center (San Antonio vs. San Luis Valley) by VAT, SAT, or SI on adiponectin concentration, indicating that the pattern of associations of these variables with adiponectin was similar in the two Hispanic groups. For these reasons, analyses in this paper were conducted categorizing the study participants according to ethnicity (Hispanic, African-American) rather than clinical center.

Anthropometric and metabolic characteristics are shown in Table 1Go, stratified by gender and ethnicity. Significant gender differences included greater VAT and waist circumference in males, and greater SAT in females (all P < 0.0001). Males had higher systolic and diastolic blood pressure, and higher concentrations of glucose and Tg, while females had higher HDL, CRP, and adiponectin (all P < 0.0001). A number of ethnic differences were also noted, including greater VAT and SI, and higher concentrations of Tg and adiponectin among Hispanics, and higher HDL among African-Americans (all P < 0.0001).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Demographic, anthropometric, and metabolic characteristics of nondiabetic subjects in the IRAS Family Study, stratified by gender and ethnicity

 
In univariate analysis, adiponectin showed notable, significant positive correlations with HDL and SI (r = 0.39 and 0.35, respectively; both P < 0.0001), and significant inverse correlations with BMI, waist circumference, fasting glucose and insulin, and VAT (r = –0.25 to –0.39; all P < 0.0001) (Table 2Go). Inverse associations with other metabolic variables, including Tg, CRP, and blood pressure, although significant, were more modest (r = –0.11 to –0.17). The magnitude and direction of these associations were consistent in separate analyses by ethnic group, the only notable differences being stronger associations of SI and VAT with adiponectin among African-Americans compared with Hispanics (Table 2Go).


View this table:
[in this window]
[in a new window]

  		TABLE 2. Spearman’s rank correlation of adiponectin with metabolic and anthropometric variables among nondiabetic IRAS Family Study participants

 
Results of multivariable backward elimination GEE analyses are shown in Table 3Go. Smoking status and Tg concentration were removed during the backward elimination procedure, and, thus, the final model included age, female gender, HDL, SAT, and SI as positive independent correlates, and glucose, CRP, and VAT as negative independent correlates. Ethnicity was not an independent correlate of adiponectin (P = 0.27). Quadratic terms for age, SAT, and SI were also retained in the model, indicating nonlinear associations of these variables with adiponectin concentration. The functional forms of these relationships for SAT and SI demonstrated positive associations of SI and SAT with adiponectin across the majority of the ranges of these variables, except at the highest levels of SI and the lowest levels of SAT (data not shown). In addition, the ethnicity by VAT interaction term was retained in the multivariable GEE model, indicating that the negative association of VAT with adiponectin differed between Hispanics and African-Americans.


View this table:
[in this window]
[in a new window]

  		TABLE 3. Multivariable determinants of adiponectin concentration in nondiabetic African-Americans and Hispanics in the IRAS Family Study

 
To explore the ethnicity by VAT interaction further, we reran the multivariable model separately for the two ethnic groups. The results, which are presented in Table 4Go, indicate a much stronger inverse association of VAT with adiponectin in African-Americans compared with Hispanics. Age, female gender, HDL, and SI were significant positive correlates of adiponectin in both groups. Fasting glucose was a weak inverse determinant in both Hispanics (P = 0.04) and African-Americans (P = 0.12), while CRP was inversely related in Hispanics (P = 0.0003), but only marginally so in African-Americans (P = 0.045).


View this table:
[in this window]
[in a new window]

  		TABLE 4. Multivariable determinants of adiponectin concentration in nondiabetic subjects, stratified by ethnicity (African-Americans vs. Hispanics) in the IRAS Family Study

 
An alternative model, using the VAT to SAT ratio in place of individual variables for VAT and SAT, generated very similar results and indicated that the VAT to SAT ratio was significantly inversely associated with adiponectin (data not shown).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
The present study assessed the metabolic correlates of adiponectin concentration in nondiabetic Hispanic and African-American adults. Specifically, we found that age, female gender, HDL concentration, SAT, and SI were significant, independent positive correlates of adiponectin, while VAT, CRP, and glucose concentrations were significant negative correlates. In addition, we found a significant ethnicity by VAT interaction, indicating a stronger inverse association of VAT with adiponectin levels among African-American compared with Hispanic participants. Ethnicity was not an independent correlate of adiponectin concentration in this model. Results of previous cross-sectional studies have consistently reported lower adiponectin levels in males (18, 19) and certain ethnic groups (11, 23, 28, 29, 30, 31, 32, 33, 34, 35); inverse associations of this adipokine with measures of adiposity, glucose, and insulin concentrations, and markers of inflammation (most commonly CRP); as well as often strong, positive associations with HDL (6, 7, 8). The present study extends this body of evidence in a number of ways, including the assessment of adiponectin correlates in a large, well characterized cohort of African-American and Hispanic subjects with direct measurements of SI, as well as VAT and SAT. The unique contributions of this study include the documentation of significant, independent contributions of directly measured SAT, VAT, and SI to variation in adiponectin levels after adjustment for covariates, and the particularly strong inverse relationship between VAT and adiponectin levels in African-American subjects.

A number of previous studies have reported lower concentrations of adiponectin in African-American subjects compared with Caucasians and other ethnic groups (11, 28, 30, 31, 32, 34, 35, 46). Various potential mechanisms have been proposed to explain these lower concentrations, including ethnic variation in adipose tissue mass or distribution (31), or differences in other metabolic syndrome components known to be related to adiponectin concentrations (32, 34). It is also likely that genetic factors are playing a role in determining adiponectin levels in African-Americans. For example, it has been previously demonstrated that the heritability of adiponectin levels is high (h2 = 0.82) among African-American subjects in the IRAS Family Study cohort (35, 46). Furthermore, it was recently reported that variants of the adiponectin gene are associated with adiponectin concentrations in white and African-American adolescents in the Princeton School District Study (17). In the present study, univariate analysis confirmed that adiponectin concentrations were significantly lower in male and female African-American participants compared with their Hispanic counterparts. Furthermore, the univariate correlates of adiponectin in African-Americans included HDL and SI (positive), as well as BMI, waist circumference, fasting glucose and insulin, VAT, Tg, and CRP (inverse), with the direction and magnitude of these correlations being very similar between the two ethnic groups. However, African-American subjects did not have significantly lower adiponectin concentrations compared with Hispanics when an ethnicity by VAT interaction term was included in the model. This observation indicates that the inverse association of VAT with adiponectin was modified by ethnicity and highlights a substantially stronger adiponectin lowering effect of VAT in African-American subjects compared with Hispanics. Therefore, the extensive risk factor characterization in the IRAS Family Study and the large sample size has allowed a determination of the possible factors that explain ethnic differences in adiponectin concentrations.

Individuals with visceral obesity, documented either indirectly using measures such as waist circumference or directly using imaging technologies such as CT, are at increased risk for type 2 diabetes and CVD (47). Furthermore, these individuals carry a heavier burden of metabolic risk factors, including insulin resistance, dyslipidemia, elevated free fatty acids, and subclinical inflammation, relative to those with lower body obesity (47, 48). More recently, hypoadiponectinemia has been added to the list of metabolic disorders associated with increased visceral adiposity. Significant inverse associations of adiponectin with surrogate measures of VAT, including waist circumference and waist-to-hip ratio, have been consistently reported in studies of human subjects, with associations between waist or waist-to-hip ratio and adiponectin often being of greater magnitude than associations with measures of overall body mass (1, 2, 3, 4, 5, 6, 7, 8). These observations have been extended by the results of a growing body of studies in which adipose tissue depots have been directly assessed using technologies such as CT (18, 25, 26, 27). In these studies, inverse correlations with adiponectin have been reported for both SAT and VAT in univariate analysis, with the magnitude of the associations often stronger for VAT. These findings are consistent with those from the current study, which involved a large sample of nondiabetic Hispanic and African-American adults. Studies of cultured visceral and sc adipocytes from humans and animal models have indicated that while both adiponectin gene expression and secretion are higher in visceral adipocytes (49, 50), adiponectin secretion from adipocytes in this depot decreases with increasing BMI (48, 51). This observation suggests a possible mechanism to explain the hypoadiponectinemia that characterizes total, and especially abdominal, obesity.

The majority of previous studies using direct assessments of adipose tissue have further indicated that the inverse associations of VAT most often remain statistically significant in multivariable analysis, whereas the magnitude and significance of SAT were often greatly attenuated. In contrast, in the present study, the association of SAT with adiponectin was significantly positive after adjustment for VAT and other variables. This observation is possibly a reflection of the adiponectin secretory capacity of adipose tissue after accounting for the down-regulating effects of visceral obesity.

SI has consistently been shown to be positively associated with adiponectin levels independently of other factors, most notably obesity measures. However, the majority of previous studies have documented this independent association using surrogate measures of SI, such as fasting insulin or indices derived from oral glucose tolerance tests. A limited number of studies have reported positive associations between adiponectin and direct measures of SI using glucose or insulin clamps, or frequently sampled iv glucose tolerance tests (23, 24) adjusted for simple measures of obesity, including BMI and waist circumference. Very limited data are available that confirm this relationship after considering direct measures of adipose tissue distribution (18). The results of the present study, in which a strong association between adiponectin and directly measured SI was documented in both Hispanics and African-Americans after adjustment for a broad range of potential confounding factors, most notably directly measured VAT and SAT, represent an important extension of this literature.

In addition to significant associations with VAT and SAT, multivariable analysis in the present study indicated that female gender, HDL (positive), and CRP (inverse) were independently associated with adiponectin concentrations. Previous studies have been remarkably consistent in documenting lower adiponectin levels in males (18, 19), an effect that may be related to the adiponectin-suppressing effect of androgens (19, 52). A strong, positive association of adiponectin with HDL has also been frequently reported in the literature (53, 54, 55, 56). The current findings and those from previous studies have shown that this association is maintained after adjustment for SI, which suggests that adiponectin may have an independent effect on hepatic lipoprotein metabolism (18, 24). A recent paper reported that hypoadiponectinemia was independently associated with increased post-heparin plasma hepatic lipase activity, which in turn could result in reductions in HDL cholesterol (57). Alternatively, this association might be explained by increases in the ligand activity of peroxisome proliferator-activated receptor-{alpha} by adiponectin (50). Activation of peroxisome proliferator-activated receptor-{alpha} is known to influence the expression of genes encoding for proteins involved in HDL metabolism (58). Finally, a growing body of literature has reported inverse associations of adiponectin with CRP and other markers of subclinical inflammation (59), observations that highlight the antiinflammatory properties of adiponectin (60).

Two issues should be kept in mind when reviewing the results of this study. First, adiponectin was measured using a commercially available RIA that determines total circulating adiponectin concentrations. Adiponectin isoform distribution (i.e. the amounts or proportions of the high and low-molecular weight forms of the protein) cannot be determined using this assay. Recent evidence suggests that the adiponectin isoform distribution, particularly the proportion of the high-molecular weight form relative to the total (an index referred to as SA), may have important physiological implications with regard to changes in SI (1) and possibly ethnic variation in adiponectin levels (61). Second, the cross-sectional design of this study does not allow for conclusions regarding the temporality of these associations. However, evidence from previous studies of animal models and humans has suggested that a decline in adiponectin concentrations may be an early event in the pathogenesis of diabetes (62), and that higher baseline adiponectin concentrations are associated with improvements over time in SI and HDL (54, 63, 64), but not with changes in body mass (54, 65). Additional human studies using longitudinal designs are needed to further clarify these relationships.

In conclusion, we found that age, female gender, HDL concentration, SAT, and SI were significant, independent positive correlates of adiponectin, while VAT, CRP, and glucose concentrations were significant negative correlates in a large, well-characterized sample of nondiabetic Hispanic and African-American adults. Understanding the factors related to variation in adiponectin concentrations is of value in light of evidence from prospective studies indicating that hypoadiponectinemia is a significant predictor of type 2 diabetes and possibly CVD, independent of other risk factors (9, 10, 11, 12, 13, 14, 15). A number of strategies have been successful in increasing adiponectin levels, including weight loss and treatment with insulin sensitizing agents, such as thiazolidinediones (20, 21, 66). Our observation that increased VAT had a stronger adiponectin lowering effect in African-American subjects compared with Hispanics is of particular interest and highlights the importance of preventing weight gain, especially in the abdominal regions, in this population.

Furthermore, this paper provides evidence needed to motivate further studies to understand how and why ethnicity alters this relationship and ultimately influences diabetes risk.


   Footnotes
 
The Insulin Resistance Atherosclerosis Family Study is supported by National Institutes of Health Grants HL60944-02, HL-61210-02, HL61019-02, HL60894, and HL60931-02. A.J.G.H. was supported by a Canadian Diabetes Association Scholarship.

Disclosure Statement: The authors have nothing to disclose.

First Published Online April 10, 2007

Abbreviations: BMI, Body mass index; CRP, C-reactive protein; CT, computed tomography; CV, coefficient of variation; CVD, cardiovascular disease; GEE, generalized estimating equation; HDL, high-density lipoprotein; IRAS, Insulin Resistance Atherosclerosis; SAT, sc adipose tissue; SI, insulin sensitivity; Tg, triglyceride; VAT, visceral adipose tissue.

Received November 28, 2006.

Accepted April 4, 2007.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Trujillo ME, Scherer PE 2005 Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257:167–175[CrossRef][Medline]
  2. Pajvani UB, Scherer PE 2003 Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 3:207–213[Medline]
  3. Fasshauer M, Paschke R, Stumvoll M 2004 Adiponectin, obesity, and cardiovascular disease. Biochimie 86:779–784[Medline]
  4. Goldstein BJ, Scalia R 2004 Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563–2568[Abstract/Free Full Text]
  5. Lam KS, Xu A 2005 Adiponectin: protection of the endothelium. Curr Diab Rep 5:254–259[Medline]
  6. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599[Abstract/Free Full Text]
  7. Matsubara M, Maruoka S, Katayose S 2002 Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764–2769[Abstract/Free Full Text]
  8. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G 2002 Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971–976[Abstract/Free Full Text]
  9. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J 2002 Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58[CrossRef][Medline]
  10. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF 2003 Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228[CrossRef][Medline]
  11. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G 2004 Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–2478[Abstract/Free Full Text]
  12. Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ 2005 The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 48:41–48[CrossRef][Medline]
  13. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB 2005 Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54:534–539[Abstract/Free Full Text]
  14. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB 2004 Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737[Abstract/Free Full Text]
  15. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N 2005 Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677–5683[Abstract/Free Full Text]
  16. Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, Haffner SM, Norris JM, Bowden DW 2005 Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet 117:107–118[CrossRef][Medline]
  17. Woo JG, Dolan LM, Deka R, Kaushal RD, Shen Y, Pal P, Daniels SR, Martin LJ 2006 Interactions between noncontiguous haplotypes in the adiponectin gene ACDC are associated with plasma adiponectin. Diabetes 55:523–529[Abstract/Free Full Text]
  18. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469[Medline]
  19. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE 2003 Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52:268–276[Abstract/Free Full Text]
  20. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM 2002 The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974[Abstract/Free Full Text]
  21. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM 2002 Synthetic peroxisome proliferator-activated receptor-{gamma} agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380[Abstract/Free Full Text]
  22. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y 2002 Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741[Abstract/Free Full Text]
  23. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935[Abstract/Free Full Text]
  24. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M 2003 Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243[Abstract/Free Full Text]
  25. Park KG, Park KS, Kim MJ, Kim HS, Suh YS, Ahn JD, Park KK, Chang YC, Lee IK 2004 Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 63:135–142[CrossRef][Medline]
  26. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S 2003 Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274–1278[CrossRef][Medline]
  27. Bacha F, Saad R, Gungor N, Arslanian SA 2004 Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and ß-cell function. Diabetes Care 27:547–552[Abstract/Free Full Text]
  28. Steffes MW, Gross MD, Schreiner PJ, Yu X, Hilner JE, Gingerich R, Jacobs Jr DR 2004 Serum adiponectin in young adults–interactions with central adiposity, circulating levels of glucose, and insulin resistance: the CARDIA study. Ann Epidemiol 14:492–498[CrossRef][Medline]
  29. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B 2004 Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration. Diabet Med 21:388–392[CrossRef][Medline]
  30. Bacha F, Saad R, Gungor N, Arslanian SA 2005 Does adiponectin explain the lower insulin sensitivity and hyperinsulinemia of African-American children? Pediatr Diabetes 6:100–102[CrossRef][Medline]
  31. Degawa-Yamauchi M, Dilts JR, Bovenkerk JE, Saha C, Pratt JH, Considine RV 2003 Lower serum adiponectin levels in African-American boys. Obes Res 11:1384–1390[Medline]
  32. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA 2004 Ethnic differences in adiponectin levels. Metabolism 53:1–3[CrossRef][Medline]
  33. Lim HS, Tayebjee MH, Tan KT, Patel JV, Macfadyen RJ, Lip GY 2005 Serum adiponectin in coronary heart disease: ethnic differences and relation to coronary artery disease severity. Heart 91:1605–1606[Free Full Text]
  34. Lee S, Bacha F, Gungor N, Arslanian SA 2006 Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 29:51–56[Abstract/Free Full Text]
  35. Guo X, Saad MF, Langefeld CD, Williams AH, Cui J, Taylor KD, Norris JM, Jinagouda S, Darwin CH, Mitchell BD, Bergman RN, Sutton B, Chen YD, Wagenknecht LE, Bowden DW, Rotter JI 2006 Genome-wide linkage of plasma adiponectin reveals a major locus on chromosome 3q distinct from the adiponectin structural gene: the IRAS Family Study. Diabetes 55:1723–1730[Abstract/Free Full Text]
  36. Hall WD, Clark LT, Wenger NK, Wright Jr JT, Kumanyika SK, Watson K, Horton EW, Flack JM, Ferdinand KC, Gavin III JR, Reed JW, Saunders E, O’Neal Jr W 2003 The metabolic syndrome in African Americans: a review. Ethn Dis 13:414–428[Medline]
  37. Caballero AE 2005 Diabetes in the Hispanic or Latino population: genes, environment, culture, and more. Curr Diab Rep 5:217–225[Medline]
  38. Henkin L, Bergman RN, Bowden DW, Ellsworth DL, Haffner SM, Langefeld CD, Mitchell BD, Norris JM, Rewers M, Saad MF, Stamm E, Wagenknecht LE, Rich SS 2003 Genetic epidemiology of insulin resistance and visceral adiposity: the IRAS Family Study Design and Methods. Ann Epidemiol 13:211–217[CrossRef][Medline]
  39. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, Bergman RN 2003 Insulin sensitivity, insulin secretion, and abdominal fat: The IRAS Family Study. Diabetes 52:2490–2496[Abstract/Free Full Text]
  40. Bergman RN, Finegood DT, Ader M 1985 Assessment of insulin sensitivity in vivo. Endocr Rev 6:45–86[Abstract/Free Full Text]
  41. Welch S, Gebhart SSP, Bergman RN, Phillips LS 1990 Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508–1518[Abstract/Free Full Text]
  42. Steil GM, Volund A, Kahn SE, Bergman RN 1993 Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes 42:250–256[Abstract]
  43. Pacini G, Bergman RN 1986 MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsitivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113–122[CrossRef][Medline]
  44. Macy EM, Hayes TE, Tracy RP 1997 Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52–58[Abstract/Free Full Text]
  45. Herbert V, Lau K, Gottlieb C, Bleicher S 1965 Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375–1384[Abstract/Free Full Text]
  46. Guo X, Saad MF, Langefeld CD, Williams AH, Cui J, Taylor KD, Norris JM, Jinagouda S, Darwin CH, Mitchell BD, Bergman RN, Sutton B, Chen YD, Wagenknecht LE, Bowden DW, Rotter JI 2006 Genome-wide linkage of plasma adiponectin reveals a major locus on chromosome 3q distinct from the adiponectin structural gene: the IRAS Family study. Diabetes 55:1723–1730[Abstract/Free Full Text]
  47. Despres JP 2001 Health consequences of visceral obesity. Ann Med 33:534–541[Medline]
  48. Lebovitz HE, Banerji MA 2005 Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 28:2322–2325[Free Full Text]
  49. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ 2002 Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667[Abstract/Free Full Text]
  50. Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N 2002 Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34:622–628[CrossRef][Medline]
  51. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S 2002 Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34:650–654[CrossRef][Medline]
  52. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073–18080
  53. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103(2):137–142
  54. Hanley AJ, Connelly PW, Harris SB, Zinman B 2003 Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 26:3219–3225[Abstract/Free Full Text]
  55. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Schaffler A 2003 Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 545:103–104[CrossRef][Medline]
  56. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, Despres JP 2005 Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90:1434–1439[Abstract/Free Full Text]
  57. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA 2005 Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 28:2181–2186[Abstract/Free Full Text]
  58. Fruchart JC2001 Peroxisome proliferator-activated receptor-{alpha} activation and high-density lipoprotein metabolism. Am J Cardiol 88:24N–29N
  59. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y 2003 Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674[Abstract/Free Full Text]
  60. Greenberg AS, Obin MS 2006 Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461S–465S
  61. Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B 2006 Low serum levels of high molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. Diabetes Care 29:1377–1379[Free Full Text]
  62. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y 2001 Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133[Abstract/Free Full Text]
  63. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA 2002 Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884–1888[Abstract/Free Full Text]
  64. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T 2004 Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87–90[Abstract/Free Full Text]
  65. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Stumvoll M, Weyer C, Tataranni PA 2002 Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 51:2964–2967[Abstract/Free Full Text]
  66. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D 2003 Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799–1804[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Diabetes CareHome page
S. H. Jain, J. M. Massaro, U. Hoffmann, G. A. Rosito, R. S. Vasan, A. Raji, C. J. O'Donnell, J. B. Meigs, and C. S. Fox
Cross-Sectional Associations Bet ween Abdominal and Thoracic Adipose Tissue Compartments and Adiponectin and Resistin in the Framingham Heart Study
Diabetes Care, May 1, 2009; 32(5): 903 - 908.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Aguilar-Salinas, E. G. Garcia, L. Robles, D. Riano, D. G. Ruiz-Gomez, A. C. Garcia-Ulloa, M. A. Melgarejo, M. Zamora, L. E. Guillen-Pineda, R. Mehta, et al.
High Adiponectin Concentrations Are Associated with the Metabolically Healthy Obese Phenotype
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4075 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener
Adiponectin and Risk of Coronary Heart Disease in Older Men and Women
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M.-F. Hivert, L. M. Sullivan, C. S. Fox, D. M. Nathan, R. B. D'Agostino Sr., P. W. F. Wilson, and J. B. Meigs
Associations of Adiponectin, Resistin, and Tumor Necrosis Factor-{alpha} with Insulin Resistance
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3165 - 3172.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. A. Kosmiski, P. Bacchetti, D. P. Kotler, S. B. Heymsfield, C. E. Lewis, M. G. Shlipak, R. Scherzer, and C. Grunfeld
Relationship of Fat Distribution with Adipokines in Human Immunodeficiency Virus Infection
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 216 - 224.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanley, A. J. G.
Right arrow Articles by Haffner, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanley, A. J. G.
Right arrow Articles by Haffner, S. M.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Metabolism

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals